Send Us Your Most Challenging Cases

Recalcitrant infections

State-of-the-art qPCR+NGS provides actionable diagnostics that can bring an end to the cycle of frustration and pain a chronically-infected UTI, prostate, or implant patient endures. Choose qPCR+NGS when diagnosing:

  • Culture-negative infections
  • Patients not responding to current treatment
  • Cases where other causes have been ruled out

MicroGenDX knows urological DNA diagnostics

MicroGenDX is the only molecular lab that has:

  • A published randomized outcome study showing its test is superior to culture, as defined by relief of symptoms
  • Identified over 5,800 different microbial species in urine, with more than 157,000 urological samples processed
  • Published data showing 96.1% concordance with culture and 12 years of CAP proficiency test results with 99.2% accuracy

NGS tells us it’s not always E.coli

E. coli may be the dominant cause for acute UTI — but for recurrent UTIs, causes are highly variable and ideal candidates for qPCR+NGS from MicroGenDX.

Among the 157,000 urine samples processed, MicroGenDX identified about 5,800 urine bacteria species and found E.coli the dominant species in only 28% of cases.

Study of the Normal Microbiome of the Urinary Tract Using NGS

Study by J. Curtis Nickel, MD, FRCSC

"The future of managing infectious disease in Urology will involve determining the pathogenic ecology of the lower urinary tract obtained with non-culture molecular diagnostic technology such as NGS," says Dr. Nickel. "Until we know what the normal microbiome looks like in healthy individuals, it will remain difficult to interpret NGS microbiome results from urine specimens submitted by symptomatic patients.”

An abstract of the completed study has been accepted by the 2021 AUA for presentation. Read more about study

Urine Pathogenicity Now Available on All Reports

As of September 1st, 2024 MicroGenDX will now be offering a pathogenicity rating on all qPCR+NGS urine samples. This rates all organisms found in that report as:
P = Known Pathogen
C = Commensal / Unlikely Pathogen
U = Unknown

This column is found to the right of the NGS% column (please see example below).  These ratings are based on an in-house developed AI algorithm.

Please note that these ratings are for healthcare provider reference only and assume the patient is not immunocompromised. The final treatment decisions rest at the physician's discretion, and all patient health factors should be taken into account. This report is currently only available for Urine Samples. 

References

  1. McDonald M, Kameh D, et al. A Head-to-Head Comparative Phase II Study of Standard Urine Culture and Sensitivity Versus DNA Next-generation Sequencing Testing for Urinary Tract Infections. Rev Urol. 2017; 19(4): 213–220. doi: 10.3909/riu0780
  2. Das R, Tseng T, Short M, et al. Next Generation Sequencing for Microbial Analysis to Select Prophylactic Antibiotic Selection before Urologic Stone Surgery: A Culture Change. Open Journal of Urology, 11, 289-304. doi: 10.4236/oju.2021.117027
  3. Nottingham C U, Assmus M A, Peters A W, et al. Next generation sequencing in patients with nephrolithiasis: how does it perform compared with standard urine and stone cultures? Ther Adv Urol, 2021, Vol 13:1-8. doi: 10.1177/1756287221994972
Show References